SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies informs about press release

26 Jul 2023 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indoco Remedies has informed that Competent Health Authority of Malta had inspected Company’s manufacturing facility for solid oral dosage form (Unit I) located at Baddi (‘Facility’), from April 20, 2023 to April 24, 2023. The Facility has received EU GMP certification from Competent Health Authority of Malta confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive. The company has enclosed press release in this regard. 

The above information is a part of company’s filings submitted to BSE.


Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×